RIVAL-01 is under clinical development by Turnstone Biologics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RIVAL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RIVAL-01 overview

TBio-6517 (RIVAL-01) is under development for the treatment of metastatic microsatellite stable colorectal cancer, metastatic, intra or extra hepatic adenocarcinoma originating from the bile duct, metastatic cutaneous melanoma, cutaneous squamous cell carcinoma of the skin, HPV associated oropharyngeal cancer and solid tumors. The vaccine candidate consisting of the vaccinia virus backbone encoding three potent immunomodulators, Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, specifically designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. It is administered through intratumor  and intravenous route. It is developed by using Vaccinia Oncolytic Viral Immunotherapy Platform. It was under development for triple negative breast cancer.

Turnstone Biologics overview

Turnstone Biologics, is a clinical stage biotech company that developing breakthrough cancer immunotherapies. The company is headquartered in Canada.

For a complete picture of RIVAL-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.